NO20042356L - Tioetersubstituerte imidazokinoliner - Google Patents

Tioetersubstituerte imidazokinoliner

Info

Publication number
NO20042356L
NO20042356L NO20042356A NO20042356A NO20042356L NO 20042356 L NO20042356 L NO 20042356L NO 20042356 A NO20042356 A NO 20042356A NO 20042356 A NO20042356 A NO 20042356A NO 20042356 L NO20042356 L NO 20042356L
Authority
NO
Norway
Prior art keywords
tioether
substituted imidazoquinolines
imidazoquinolines
substituted
Prior art date
Application number
NO20042356A
Other languages
English (en)
Other versions
NO329000B1 (no
Inventor
Bryon A Merrill
Matthew R Radmer
Jason D Bonk
Jr Joseph F Dellaria
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of NO20042356L publication Critical patent/NO20042356L/no
Publication of NO329000B1 publication Critical patent/NO329000B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20042356A 2001-12-06 2004-06-07 Tioetersubstituerte imidazokinoliner NO329000B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/013,059 US6664264B2 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
PCT/US2002/018290 WO2003050121A1 (en) 2001-12-06 2002-06-07 Thioether substituted imidazoquinolines

Publications (2)

Publication Number Publication Date
NO20042356L true NO20042356L (no) 2004-08-12
NO329000B1 NO329000B1 (no) 2010-07-19

Family

ID=21758095

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042356A NO329000B1 (no) 2001-12-06 2004-06-07 Tioetersubstituerte imidazokinoliner

Country Status (16)

Country Link
US (3) US6664264B2 (no)
EP (1) EP1451191A1 (no)
JP (2) JP2005511747A (no)
KR (1) KR20040105692A (no)
CN (1) CN1235900C (no)
BR (1) BR0214750A (no)
CA (1) CA2468517C (no)
HR (1) HRP20040505A2 (no)
IL (1) IL162054A0 (no)
MX (1) MXPA04005362A (no)
NO (1) NO329000B1 (no)
NZ (1) NZ533038A (no)
PL (1) PL370661A1 (no)
RU (1) RU2304143C2 (no)
WO (1) WO2003050121A1 (no)
ZA (1) ZA200405338B (no)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
CA2475595C (en) 2002-02-22 2012-07-10 3M Innovative Properties Company Method of reducing and preventing uvb-induced immunosuppression
WO2003103584A2 (en) 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
CA2510375A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
JP2006512391A (ja) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
JP2006519020A (ja) * 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Tlr介在生物活性の選択的調節
WO2004078138A2 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
JP2006519877A (ja) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー 1−アミノ1h−イミダゾキノリン
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
EP1603476A4 (en) 2003-03-13 2010-01-13 3M Innovative Properties Co PROCESS FOR REMOVING TATTOO
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
NZ567227A (en) * 2003-03-13 2010-01-29 3M Innovative Properties Co Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2004108072A2 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
AR044466A1 (es) * 2003-06-06 2005-09-14 3M Innovative Properties Co Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
JP2007501252A (ja) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
AR045261A1 (es) * 2003-08-12 2005-10-19 3M Innovative Properties Co Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores
US7799800B2 (en) * 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
JP2007503268A (ja) 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
ES2406730T3 (es) * 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
EP1663222A4 (en) * 2003-09-02 2008-05-21 3M Innovative Properties Co METHODS RELATING TO THE TREATMENT OF GIANCES
ES2342069T4 (es) * 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.
AU2004270201A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
EP1664342A4 (en) * 2003-09-17 2007-12-26 3M Innovative Properties Co SELECTIVE MODULATION OF TLR GENE EXPRESSION
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
NZ546274A (en) 2003-10-03 2009-12-24 3M Innovative Properties Co Pyrazolopyridines and analags thereof
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US7897767B2 (en) * 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
EP1686992A4 (en) * 2003-11-25 2009-11-04 3M Innovative Properties Co HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME
MXPA06005910A (es) 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
EP1689361A4 (en) 2003-12-02 2009-06-17 3M Innovative Properties Co THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS
JP2007513170A (ja) * 2003-12-04 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー スルホン置換イミダゾ環エーテル
US7888349B2 (en) * 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
EP1701955A1 (en) * 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20070167479A1 (en) * 2004-03-15 2007-07-19 Busch Terri F Immune response modifier formulations and methods
CA2559863A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
AU2005244260B2 (en) * 2004-04-09 2010-08-05 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
EP1765348B1 (en) * 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8143270B2 (en) 2004-09-02 2012-03-27 3M Innovative Properties Company 2-amino 1H-in-imidazo ring systems and methods
US7579359B2 (en) * 2004-09-02 2009-08-25 3M Innovative Properties Company 1-alkoxy 1H-imidazo ring systems and methods
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
EP1797091A2 (en) * 2004-09-14 2007-06-20 Novartis Vaccines and Diagnostics, Inc. Imidazoquinoline compounds
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
PL1824482T3 (pl) 2004-12-17 2014-07-31 Anadys Pharmaceuticals Inc 3,5-Dipodstawione oraz 3,5,7-tripodstawione związki 3H-oksazolo- oraz 3H-tiazolo[4,5-d]pirymidyn-2-onowe i ich proleki
BRPI0519302A2 (pt) * 2004-12-30 2009-01-06 Takeda Pharmaceutical etanossulfonato de sais de 1-(2-metilpropil)-1h-imidazo[4,5-c][1,5]naftiridin-4-amin o e metanossulfonato de 1-(2-metilpropil)-1h-imidazo[4,5-c][1,5]naftiridin-4-amin a, composiÇÕes contendo os mesmos, processos de preparaÇço e uso
ES2392648T3 (es) 2004-12-30 2012-12-12 3M Innovative Properties Company Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
PT1830876E (pt) 2004-12-30 2015-07-13 Meda Ab Utilização de imiquimod para o tratamento de metástases cutâneas derivadas de um tumor cancerígeno da mama
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
WO2007120121A2 (en) 2005-02-09 2007-10-25 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
EP1846419B1 (en) 2005-02-09 2014-04-16 3M Innovative Properties Company Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
JP2008531568A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ,インコーポレイテッド ヒドロキシアルキルで置換されたイミダゾナフチリジン
JP2008543725A (ja) 2005-02-23 2008-12-04 コーリー ファーマシューティカル グループ,インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン
AU2006216686A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
MX2007011112A (es) 2005-03-14 2007-11-07 Graceway Pharmaceuticals Llc Metodo para tratar queratosis actinica.
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
JP2008538550A (ja) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ,インコーポレイテッド ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての1−置換ピラゾロ(3,4−c)環状化合物
JP2009501546A (ja) 2005-07-18 2009-01-22 ノバルティス アーゲー Hcv複製についての小動物モデル
CA2621831A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
JP5247458B2 (ja) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換1h−イミダゾキノリン及び方法
PL1951299T3 (pl) 2005-11-04 2012-07-31 Novartis Ag Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
SG152296A1 (en) 2005-11-21 2009-05-29 Anadys Pharmaceuticals Inc Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
WO2007150002A2 (en) * 2006-06-22 2007-12-27 Anadys Pharmaceuticals, Inc. PRODRUGS OF 5-AMINO-3-(3'-DEOXY-β-D-RIBOFURANOSYL)-THIAZOLO[4,5-d] PYRIMIDIN-2,7-DIONE
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
BRPI0714831A2 (pt) 2006-07-18 2013-04-02 Anadys Pharmaceuticals Inc composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
WO2008032219A2 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
HRP20120790T1 (hr) 2007-06-27 2013-01-31 Novartis Ag Cjepiva protiv influence sa niskom koliäśinom aditiva
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
ES2535101T3 (es) 2008-03-18 2015-05-05 Novartis Ag Mejoras en la preparación de antígenos en vacuna de virus de la gripe
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
TWI444044B (zh) * 2009-03-31 2014-07-01 Ibm 遠距應用中傳輸資料之裝置、方法與電腦程式產品
WO2010119343A2 (en) 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
CA2763816A1 (en) 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
CA2808624C (en) 2010-08-17 2019-05-14 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
PL2667892T3 (pl) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Schemat szczepień przeciwko rsv
ES2651143T3 (es) 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3366311B1 (en) 2011-06-03 2020-02-26 3M Innovative Properties Co. Hydrazino-1h-imidazoquinolin-4-amines and conjugates made therefrom
US9493517B2 (en) 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
DK2941233T3 (da) 2013-01-07 2020-10-19 Univ Pennsylvania Sammensætninger og fremgangsmåder til behandling af kutant T-celle-lymfom
MX2016005996A (es) 2013-11-05 2016-08-11 3M Innovative Properties Co Formulaciones de inyeccion con base en aceite de ajonjoli.
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
AU2015205753A1 (en) 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating HER2 positive tumors
EA037818B1 (ru) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Мутантные стафилококковые антигены
CN112546230A (zh) * 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
EA201790369A1 (ru) 2014-09-16 2017-10-31 Джилид Сайэнс, Инк. Твердые формы модулятора толл-подобного рецептора
EP3344623B1 (en) 2015-08-31 2021-02-17 3M Innovative Properties Company Imidazo[4,5-c]ring compounds containing substituted guanidine groups
EP3344622B1 (en) 2015-08-31 2021-07-07 3M Innovative Properties Company Guanidine substituted, fused 1h-imidazo[4,5-c]pyridine compounds useful in the treatment of viral and neoplastic diseases
CN108137586B (zh) * 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-egfr组合
WO2018038877A1 (en) 2016-08-26 2018-03-01 3M Innovative Properties Company FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS
EP3589631B1 (en) 2017-03-01 2021-07-21 3M Innovative Properties Company Imidazo[4,5-c]ring compounds containing guanidine substituted benzamide groups
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
KR20200019226A (ko) 2017-06-23 2020-02-21 버디 바이오파마슈티칼즈, 인크. 약학 조성물
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CA3092545A1 (en) 2018-02-28 2019-09-06 3M Innovative Properties Company Substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
EP3759129A1 (en) 2018-02-28 2021-01-06 Pfizer Inc Il-15 variants and uses thereof
EP3796983A2 (en) 2018-05-23 2021-03-31 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
PL3797121T3 (pl) 2018-05-23 2024-09-23 Pfizer Inc. Przeciwciała swoiste dla CD3 i ich zastosowania
CA3101277A1 (en) 2018-05-24 2019-11-28 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
EP3887369B1 (en) 2018-11-26 2024-05-08 Solventum Intellectual Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US20220177471A1 (en) 2019-06-06 2022-06-09 3M Innovative Properties Company N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
EP3983408A1 (en) 2019-06-12 2022-04-20 3M Innovative Properties Company Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Cd47、pd-l1に特異的な抗体、およびその使用
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3692907A (en) * 1970-10-27 1972-09-19 Richardson Merrell Inc Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4928624A (en) * 1987-02-09 1990-05-29 Overton Jr Duncan E Powder spray booth with overspray collection system
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
DE8902903U1 (de) * 1989-03-09 1989-08-10 Lechmetall Landsberg GmbH Edelstahlerzeugnisse, 8910 Landsberg Gargerät
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
HU217080B (hu) * 1990-10-05 1999-11-29 Minnesota Mining And Manufacturing Co. Új eljárás imidazo[4,5-c]kinolin-4-amin-származékok előállítására
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
EP0582581B1 (en) * 1991-03-01 1999-05-06 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5900475A (en) * 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5367706A (en) * 1993-07-19 1994-11-29 Davidson; Norma J. Collapsible headnet
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
JPH09208584A (ja) 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
JPH09255926A (ja) 1996-03-26 1997-09-30 Diatex Co Ltd 粘着テープ
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
ES2290969T3 (es) * 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
WO1998030562A1 (en) 1997-01-09 1998-07-16 Terumo Kabushiki Kaisha Novel amide derivatives and intermediates for the synthesis thereof
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
JPH11222432A (ja) 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
JPH11255926A (ja) 1998-03-13 1999-09-21 Toray Ind Inc シリコーン成型品およびその製造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h―イミダゾピリジン誘導体
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6245776B1 (en) * 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (ja) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (ja) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) * 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
AU2002232498B2 (en) * 2000-12-08 2006-05-04 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
JP2005519849A (ja) 2001-06-15 2005-07-07 スリーエム イノベイティブ プロパティズ カンパニー 歯周病の治療用免疫応答調節剤
CA2458876A1 (en) 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040014779A1 (en) 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
DE60228611D1 (de) 2001-11-29 2008-10-09 3M Innovative Properties Co Pharmazeutische formulierung umfassend ein die immunantwort modifizierendes mittel
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
CA2475595C (en) * 2002-02-22 2012-07-10 3M Innovative Properties Company Method of reducing and preventing uvb-induced immunosuppression
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US6743920B2 (en) * 2002-05-29 2004-06-01 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2003103584A2 (en) * 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
ATE488246T1 (de) * 2002-08-15 2010-12-15 3M Innovative Properties Co Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
JP2006503068A (ja) * 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1h−イミダゾダイマー
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
CA2510375A1 (en) * 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
JP2006512391A (ja) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
JP2006519020A (ja) * 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Tlr介在生物活性の選択的調節
WO2004078138A2 (en) * 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
JP2006519877A (ja) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー 1−アミノ1h−イミダゾキノリン
NZ567227A (en) * 2003-03-13 2010-01-29 3M Innovative Properties Co Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
EP1603476A4 (en) * 2003-03-13 2010-01-13 3M Innovative Properties Co PROCESS FOR REMOVING TATTOO
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
US20040191833A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
WO2004108072A2 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
ES2342069T4 (es) * 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.

Also Published As

Publication number Publication date
CN1235900C (zh) 2006-01-11
PL370661A1 (en) 2005-05-30
EP1451191A1 (en) 2004-09-01
JP2005511747A (ja) 2005-04-28
NO329000B1 (no) 2010-07-19
BR0214750A (pt) 2004-09-14
US20020173655A1 (en) 2002-11-21
JP5319477B2 (ja) 2013-10-16
HRP20040505A2 (en) 2004-12-31
US7288550B2 (en) 2007-10-30
US6921826B2 (en) 2005-07-26
US20050209267A1 (en) 2005-09-22
RU2004117160A (ru) 2006-01-10
NZ533038A (en) 2005-12-23
CA2468517A1 (en) 2003-06-19
AU2002315009A1 (en) 2003-06-23
ZA200405338B (en) 2005-07-12
KR20040105692A (ko) 2004-12-16
US20040102471A1 (en) 2004-05-27
MXPA04005362A (es) 2004-09-27
RU2304143C2 (ru) 2007-08-10
WO2003050121A1 (en) 2003-06-19
JP2010031024A (ja) 2010-02-12
CN1599741A (zh) 2005-03-23
IL162054A0 (en) 2005-11-20
CA2468517C (en) 2011-01-04
US6664264B2 (en) 2003-12-16

Similar Documents

Publication Publication Date Title
NO20042356L (no) Tioetersubstituerte imidazokinoliner
DK1341791T3 (da) Thioethersubstituerede imidazoquinoliner
DK1671949T3 (da) Substituerede pyridinylaminer
ATE319451T1 (de) Tetrahydrochinolin-derivate
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
DE50103741D1 (de) Welle-Nabe-Verbindung
DE50206892D1 (de) Substituierte imidazotriazinone
ATE335486T1 (de) Hydrazono-malonitrile
IS2523B (is) Turn vindorkuvers
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DE50203412D1 (de) Schwenkkolbenverdränger
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
ATE355059T1 (de) Isoxazolopyridinone
ATE435197T1 (de) Substituierte 4-aminocyclohexanole
DE50201862D1 (de) Messwandler
DE50203093D1 (de) Losradlager
ATA18372001A (de) Gelenksbolzenbaueinheit
ATE319694T1 (de) Phenylalkyne
DE60202381D1 (de) Paroxetin-n-formyl-derivate
DE50202088D1 (de) Garmodulsystem
ATA13992002A (de) Schlackengranulierungsanlage
DE50202045D1 (de) Leitungsanordnung
DE50108381D1 (de) Synchronisierschaltungsanordnung
DE10295006D2 (de) Bauwerksabdichtung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees